| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/13543784.2016.1189901 |
| P698 | PubMed publication ID | 27186892 |
| P50 | author | Kunal Nepali | Q89110255 |
| Jing-Ping Liou | Q89110260 | ||
| Hsueh-Yun Lee | Q89110262 | ||
| Ritu Ojha | Q99741360 | ||
| P2860 | cites work | The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. | Q52933092 |
| Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines. | Q54116661 | ||
| Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. | Q54502551 | ||
| Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. | Q54974194 | ||
| TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. | Q55040537 | ||
| Tubulin-interactive natural products as anticancer agents | Q24650163 | ||
| A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs | Q24651931 | ||
| Molecular mechanism of action of microtubule-stabilizing anticancer agents | Q27683695 | ||
| The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization | Q27689074 | ||
| Microtubule-binding agents: a dynamic field of cancer therapeutics | Q27690249 | ||
| Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts | Q28482576 | ||
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
| Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties | Q31024172 | ||
| Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity | Q33248747 | ||
| A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. | Q33370110 | ||
| Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. | Q33403026 | ||
| Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies | Q33423203 | ||
| Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death | Q33539855 | ||
| A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours | Q33555237 | ||
| A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome | Q34035391 | ||
| Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling | Q34078666 | ||
| The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents | Q34122191 | ||
| Microtubule-binding natural products for cancer therapy | Q34122669 | ||
| Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas | Q34153679 | ||
| A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer | Q34322294 | ||
| Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer | Q34393640 | ||
| Structure activity relationship of arylidene pyrrolo and pyrido [2,1-b] quinazolones as cytotoxic agents: synthesis, SAR studies, biological evaluation and docking studies. | Q34444379 | ||
| NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent | Q34471405 | ||
| The biology of the combretastatins as tumour vascular targeting agents | Q34680614 | ||
| Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance | Q34996744 | ||
| Microtubule-stabilizing marine metabolite laulimalide and its derivatives: synthetic approaches and antitumor activity | Q35215646 | ||
| Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program | Q35513763 | ||
| Vascular targeting agents as cancer therapeutics | Q35647684 | ||
| Combretastatin A4 phosphate: background and current clinical status | Q35871932 | ||
| A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. | Q35920803 | ||
| Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial | Q35998447 | ||
| Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. | Q36317237 | ||
| Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer | Q36352822 | ||
| Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. | Q36433061 | ||
| Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors | Q36482522 | ||
| Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin | Q36804154 | ||
| An overview of tubulin inhibitors that interact with the colchicine binding site | Q36885540 | ||
| A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer | Q36895058 | ||
| Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study | Q37121635 | ||
| Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy | Q37125330 | ||
| Vascular targeted therapies in oncology | Q37254370 | ||
| Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects | Q37303584 | ||
| Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). | Q37450554 | ||
| Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. | Q37694429 | ||
| Antimitotic inhibitors | Q38004216 | ||
| Vascular attack as a therapeutic strategy for cancer | Q38037849 | ||
| Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB). | Q38147920 | ||
| Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments | Q38331887 | ||
| Identification of CKD-516: A Potent Tubulin Polymerization Inhibitor with Marked Antitumor Activity against Murine and Human Solid Tumors | Q38482781 | ||
| Antimitotic and antivascular activity of heteroaroyl-2-hydroxy-3,4,5-trimethoxybenzenes | Q38854814 | ||
| TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells | Q39005489 | ||
| Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities | Q39488461 | ||
| Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent | Q39636226 | ||
| BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. | Q39697801 | ||
| Antitumor and antivascular effects of AVE8062 in ovarian carcinoma | Q40073585 | ||
| A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. | Q40105258 | ||
| MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps | Q40118483 | ||
| Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma | Q40227957 | ||
| Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours | Q40389914 | ||
| Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. | Q40465248 | ||
| Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine | Q40485772 | ||
| BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. | Q40539646 | ||
| Novel oral taxane therapies: recent Phase I results | Q40766794 | ||
| The mechanism of action of colchicine. Colchicine binding properties of sea urchin sperm tail outer doublet tubulin | Q41172364 | ||
| Microtubules and actin filaments: dynamic targets for cancer chemotherapy | Q41713562 | ||
| Transporter-mediated protection against thiopurine-induced hematopoietic toxicity | Q42222648 | ||
| Tumor targeting by conjugation of DHA to paclitaxel | Q43698653 | ||
| Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476. | Q43821262 | ||
| The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. | Q44064731 | ||
| Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo | Q44412196 | ||
| DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo | Q44490316 | ||
| Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). | Q44558813 | ||
| Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo | Q44580396 | ||
| Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies | Q44937628 | ||
| Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis | Q44967775 | ||
| Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. | Q45972029 | ||
| Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors | Q46160687 | ||
| Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours | Q46167877 | ||
| A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma | Q46188537 | ||
| Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial | Q46404675 | ||
| Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals | Q46946340 | ||
| Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle | Q47846165 | ||
| The pediatric preclinical testing program: description of models and early testing results. | Q48387109 | ||
| Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors | Q48511935 | ||
| Antitumor activity of TZT-1027, a novel dolastatin 10 derivative | Q48773255 | ||
| A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. | Q50798185 | ||
| Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? | Q51793589 | ||
| Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. | Q52542436 | ||
| Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. | Q52573502 | ||
| Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. | Q52608144 | ||
| Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. | Q52612765 | ||
| Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. | Q52620379 | ||
| Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. | Q52625890 | ||
| The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. | Q52627703 | ||
| Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. | Q52641965 | ||
| DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer. | Q52650698 | ||
| Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. | Q52650797 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 917-936 | |
| P577 | publication date | 2016-05-17 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Early investigational tubulin inhibitors as novel cancer therapeutics | |
| P478 | volume | 25 |
| Q38680790 | A 4-Phenoxyphenol Derivative Exerts Inhibitory Effects on Human Hepatocellular Carcinoma Cells through Regulating Autophagy and Apoptosis Accompanied by Downregulating α-Tubulin Expression. |
| Q52624664 | A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo. |
| Q93024854 | Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients |
| Q51795514 | Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer. |
Search more.